Group 1 - NTT Data plans to increase its workforce in India by 5,000 employees this year, focusing on software programming, consulting, and IT support [1] - The company has seen a doubling of large IT contracts exceeding $100 million in the past year, particularly in manufacturing, logistics, and the public sector [1] - NTT Data is currently constructing four data centers in India as part of a $1.5 billion investment, with a current workforce of 40,000 in the country [2] Group 2 - The Indian data center market is attractive due to the country hosting 20% of the world's data but having less than 6% of global data center capacity [2] - Clients' technology budgets are projected to increase by 7% to 9% this year, up from 6% to 7% last year, driven by investments beyond AI [3]

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to a loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.01%. A quarter ago, it was expected that this company would post a loss of $1.27 per share when it actually produced a loss of $1.38, delivering a surprise of -8.66%.Over the last four quarters, the co ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlan Krasner - Chief EndocrinologistCatherine Novack - Director of Healthcare Equity ResearchGayathri Diwakar - Head of Investor RelationsIsabel Kalofonos - Chief Commercial OfficerScott Struthers - Founder and CEOToby Schilke - CFOConference Call ParticipantsAlex Thompson - Senior Equity Research AnalystAndy Chen - Director and Senior Equity Research AnalystDennis Ding - VP and Equity Research ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlan Krasner - Chief EndocrinologistCatherine Novack - Director of Healthcare Equity ResearchGayathri Diwakar - Head of Investor RelationsIsabel Kalofonos - Chief Commercial OfficerScott Struthers - Founder and CEOToby Schilke - CFOConference Call ParticipantsAlex Thompson - Senior Equity Research AnalystAndy Chen - Director and Senior Equity Research AnalystDennis Ding - VP and Equity Research ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker14Welcome to Crinetics Pharmaceuticals' fourth quarter and full year 2025 financial results conference call. At this time, all participants are in listen only mode. Following management's prepared remarks, we will hold a question and answer session. In order to ask a question, please press star then 1 on your telephone. I'd now like to turn the call over to Gayathri Diwakar, Head of Investor Relations. Pleas ...

February 26, 2026 Fourth Quarter and Full Year 2025 Financial Results and Business Update Forward Looking Statements This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: our ability to effectively comme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ____________________________________________________________ Form 10-K ____________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a gl ...

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 13 hot stocks to buy with the highest upside potential. On January 30, Stifel raised its price target on Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) to $84 from $75, while maintaining its Buy rating, noting that the company’s pre-report for the fourth quarter of 2025 went better than early investor expectations for the first quarter of the launch of Palsonify, an FDA-approved, once-daily oral medication for treating adults with acromegaly. Meanwh ...

Core Insights - Crinetics Pharmaceuticals, Inc. will participate in two upcoming investor conferences, providing opportunities for 1x1 meetings with management [1][2] - The company focuses on transforming the treatment of endocrine diseases and related tumors through innovative therapies [3] - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for acromegaly, with additional programs in development for various endocrine conditions [4] Group 1: Upcoming Events - Crinetics will attend the TD Cowen 46 Annual Health Care Conference in Boston on March 4, 2026, with a fireside chat scheduled for 1:50 p.m. Eastern Time [1] - Management will also be available for 1x1 meetings on March 4, 2026, and at the Leerink Annual Global Healthcare Conference in Miami on March 11, 2026 [1] Group 2: Company Overview - Crinetics Pharmaceuticals is dedicated to discovering, developing, and commercializing novel therapies targeting G-protein coupled receptors (GPCRs) [3] - The company has a pipeline of over 10 disclosed programs, including late-stage candidates for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [4] - Additional discovery programs address various endocrine conditions such as Graves' disease, polycystic kidney disease, and GPCR-targeted oncology indications [4]